Keywords: Novartis, Cellectis, Homologous recombination, GenVec, Hearing loss, Balance disorders
Novartis in licensing deal with Cellectis; pays milestone to GenVec
Article | 07 December 2011
Paris, France-based Cellectis genome engineering specialist (Alternext: ALCLS) has signed a license agreement with Swiss drug major Novartis (NOVN: VX) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
